SLC1A2 and amyotrophic lateral sclerosis: Ceftriaxone, a beta-lactam antibiotic, showed negative results in preventing ALS deterioration in spite of its increased EAAT2 activity [32], partially due to the lack of a pharmacodynamic marker of ceftriaxone to upregulate glutamate transporter in patients with ALS.